HeyJaredGSK Media
- Indexed articles, last 90 days
- 13
- Latest publication
- Jul 29, 2026
- Outlet visibility, for GSK
- Top 500K sites
- Earliest in this view
- Jul 9, 2026
Latest articles
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 (opens the original)
Read excerpt
Superiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK (opens the original)
Read excerpt
Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026 (opens the original)
Read excerpt
Q2 results 2026
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China (opens the original)
Read excerpt
ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV (opens the original)
Read excerpt
Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For GSK, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.